CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleRevenue is $720.53M, above the global median of $520.53M
- FinancialsAltman Z-Score 2.29: grey zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
870.61MUSDvs all stocks (USD)
Trailing P/E
11.96xRevenue (TTM)
720.53MUSDvs all stocks (USD)
Profit Margin
11.00%Beta
0.8880xvs all stocks
52-Week Change
-6.80%vs all stocks
Market Capitalization
870.61MUSDvs all stocks (USD)
Enterprise Value
1.27BUSDvs all stocks (USD)
Trailing P/E
11.96xForward P/E
6.53xPEG Ratio
-0.1626xPrice to Sales (TTM)
1.22xPrice to Book (MRQ)
1.15xEnterprise to Revenue
1.76xEnterprise to EBITDA
6.44xGross Margin
41.08%Profit Margin
11.00%Operating Margin
7.96%Return on Assets (TTM)
5.34%Return on Equity (TTM)
10.39%Revenue (TTM)
720.53MUSDvs all stocks (USD)
Revenue per Share (TTM)
15.61USDUpdated Jul 18, 2026Quarterly Revenue Growth
0.40%Gross Profit (TTM)
341.13MUSDvs all stocks (USD)
EBITDA (TTM)
193.05MUSDvs all stocks (USD)
Net Income (TTM)
79.23MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-74.60%Operating Cash Flow (TTM)
168.88MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
103.10MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%Revenue
719.89MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
363.83MUSDFY2025 · Dec 31, 2025Gross Profit
356.06MUSDFY2025 · Dec 31, 2025Operating Income
140.40MUSDvs all stocks (USD)
Pre-tax Income
123.62MUSDFY2025 · Dec 31, 2025Income Tax Expense
25.53MUSDFY2025 · Dec 31, 2025Net Income
98.09MUSDFY2025 · Dec 31, 2025EBIT
149.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
212.31MUSDFY2025 · Dec 31, 2025Research & Development
85.84MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
129.81MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
8.68MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
25.48MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.10USDFY2025 · Dec 31, 2025EPS (Diluted)
2.03USDFY2025 · Dec 31, 2025Basic Shares Outstanding
46.74MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
46.74MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
98.09MUSDFY2025 · Dec 31, 2025Operating Cash Flow
157.11MUSDFY2025 · Dec 31, 2025Free Cash Flow
122.23MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
170.41MUSDFY2025 · Dec 31, 2025Income Tax Paid
22.71MUSDFY2025 · Dec 31, 2025Interest Paid
23.22MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
98.09MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
63.20MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
27.63MUSDFY2025 · Dec 31, 2025Stock-based Compensation
27.28MUSDFY2025 · Dec 31, 2025Other Non-cash Items
3.35MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-6.37MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-4.56MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-51.52MUSDFY2025 · Dec 31, 2025Capital Expenditures
-34.88MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-2.25MUSDFY2025 · Dec 31, 2025Net Acquisitions
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
-119.13MUSDFY2025 · Dec 31, 2025Sale of Investments
90.29MUSDFY2025 · Dec 31, 2025Other Investing Activity
-4.36MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-68.08MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
6.22MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-223.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-75.59MUSDFY2025 · Dec 31, 2025Other Financing Charges
-687.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-70.28MUSDFY2025 · Dec 31, 2025Shares Outstanding
44.64MSharesUpdated Jul 18, 2026Float Shares
32.83MSharesUpdated Jul 18, 2026Shares Short
3.85MSharesUpdated Jul 18, 2026Short Ratio
6.04daysvs all stocks
Short % of Shares Outstanding
18.25%vs all stocks
% Held by Insiders
29.74%vs all stocks
% Held by Institutions
77.26%vs all stocks
Total Cash (MRQ)
291.95MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.62USDUpdated Jul 18, 2026Total Debt (MRQ)
686.38MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.8875xCurrent Ratio (MRQ)
3.85xBook Value per Share (MRQ)
17.33USDUpdated Jul 18, 2026Total Assets
1.63BUSDvs all stocks (USD)
Total Current Assets
636.02MUSDFY2025 · Dec 31, 2025Total Liabilities
840.49MUSDFY2025 · Dec 31, 2025Total Non-current Assets
993.28MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
682.34MUSDFY2025 · Dec 31, 2025Total Current Liabilities
158.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
170.18MUSDFY2025 · Dec 31, 2025Other Short-term Investments
112.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
143.56MUSDFY2025 · Dec 31, 2025Inventory
176.89MUSDFY2025 · Dec 31, 2025Accounts Payable
32.59MUSDFY2025 · Dec 31, 2025Short-term Debt
9.57MUSDFY2025 · Dec 31, 2025Long-term Debt
646.43MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
29.98MUSDFY2025 · Dec 31, 2025Common Stock (Book)
6.00KUSDFY2025 · Dec 31, 2025Retained Earnings
666.88MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
788.80MUSDvs all stocks (USD)
Treasury Stock
408.15MUSDFY2025 · Dec 31, 202552-Week Low
16.65USDUpdated Jul 18, 202652-Week High
31.26USDUpdated Jul 18, 202652-Week Change
-6.80%vs all stocks
Beta
0.8880xvs all stocks
50-Day MA
19.45USDUpdated Jul 18, 2026200-Day MA
23.29USDUpdated Jul 18, 2026Avg 10-Day Volume
375.50KSharesUpdated Jul 18, 2026Avg 30-Day Volume
538.62KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
1.66USDUpdated Jul 18, 2026Other Income / Expense
23.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
Drawdown With FCF And Cash Backing
Well below its peak, with three years of positive free cash flow behind it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Prioritizing buybacks over growth reinvestmentNotable
Buyback Intensity: 0.09Revenue Growth YoY: 0.00
Financial Health
Altman Z-Score 2.29: grey zoneSignificant
Altman Z-Score: 2.29
High earnings qualityNotable
Earnings Quality Score: 0.96
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Revenue is $720.53M, above the global median of $520.53MNotable
Revenue (USD): 720,529,984Global Median: 520,528,949.311
Levered free cash flow is $103.1M, above the global median of $16.24MNotable
Levered free cash flow (USD): 103,104,496Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Oxford Biomedica plc
Tier 1ProductionApproval-Gated PipelineFlowRule
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinghua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Heilongjiang ZBD Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Hunan Warrants Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanghai Kaibao Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Theravance Biopharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Boji Medical & Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Replimune Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nature's Sunshine Products Inc.
2 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With Profitability
Beijing SDL Technology Co. Ltd.
2 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With Profitability
Guiyang Xintian Pharmaceutical Co., Ltd.
2 interpretationsDrawdown With FCF And Cash BackingClose Below 40W SMA With Profitability